Pascal Deschatelets - 24 Jun 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol
APLS
Transactions as of
24 Jun 2021
Net transactions value
-$393,375
Form type
4
Filing time
25 Jun 2021, 21:48:46 UTC
Previous filing
25 May 2021
Next filing
25 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $16,688 +6,250 +0.72% $2.67* 875,837 24 Jun 2021 Direct F1
transaction APLS Common Stock Sale $410,062 -6,250 -0.71% $65.61 869,587 24 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -6,250 -1.7% $0.000000 368,999 24 Jun 2021 Common Stock 6,250 $2.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise from 10B5-1 trading plan.
F2 This stock option was granted on 12/5/2013 and is fully vested.